Sensei Biotherapeutics completed the acquisition of Faeth Therapeutics on February 17 2026 in a stock‑for‑stock transaction, issuing 252,210 shares of its common stock to Faeth shareholders.
The company also closed a $200 million private placement of Series B non‑voting convertible preferred stock. Proceeds will fund the advancement of Faeth’s lead asset, PIKTOR, through Phase 2 trials in endometrial cancer and Phase 1b trials in breast cancer, and will support the completion of Sensei’s ongoing solnerstotug study and integration of Faeth’s assets.
The deal represents a strategic pivot for Sensei, which had recently discontinued its sole clinical program, solnerstotug, and entered a comprehensive strategic review. By adding Faeth’s PI3K/AKT/mTOR platform, Sensei broadens its pipeline and positions itself for future collaboration or acquisition opportunities in oncology.
Anand Parikh, co‑founder of Faeth and now COO of Sensei, explained the therapeutic rationale for PIKTOR: “In the PI3K pathway, the field has repeatedly run into the same constraint. Single‑node inhibitors force a tradeoff between efficacy and tolerability. PIKTOR is designed to change that tradeoff by inhibiting PI3K‑alpha and mTORC1/2 simultaneously, and we believe we can achieve more complete pathway suppression with improved tolerability.”
Investors reacted positively to the combined transaction, viewing the acquisition and financing as a lifeline that restores a viable clinical pipeline and provides the capital needed to advance key programs.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.